Products for Research Use Only

Diphenhydramine

CAT: 0804-HY-B0303-01Size: 250 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0303-01Size:250 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Diphenhydramine is a first-generation histamine H1-receptor antagonist with anti-cholinergic effect. Diphenhydramine hydrochloride can across the ovine blood-brain barrier (BBB) [1][2][3].
CAS Number
58-73-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Bacterial; Endogenous Metabolite; Histamine Receptor; iGluR
Type
Reference compound
Related Pathways
Anti-infection; GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/diphenhydramine.html
Concentration
10mM
Purity
99.56
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
Molecular Formula
C17H21NO
Molecular Weight
255.36
Precautions
H302, H315, H319, H335
References & Citations
[1]Jason P Berninger, et al. Effects of the antihistamine diphenhydramine on selected aquatic organisms. Environ Toxicol Chem. 2011 Sep;30 (9) :2065-72.|[2]Föhr KJ, et al. Open channel block of NMDA receptors by diphenhydramine. Neuropharmacology. 2015 Dec;99:459-70. |[3]Ehling S, et al. Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. Vet Dermatol. 2019 Apr;30 (2) :91-e24. |[4]Hamano H, et al. Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity. Kidney Int. 2021 Apr;99 (4) :885-899.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
H1 Receptor; NMDA Receptor
Citation 01
Acta Pharmacol Sin. 2024 Oct;45 (10) :2061-2076.|Pharm Res. 2025 Oct 27.|bioRxiv. 2025 Sep 10:2025.09.05.673576.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2022 Nov 8;41 (6) :111615.|Chemosphere. 2019 Jun:225:378-387.|Pharmacol Res Perspect. 2021 Oct;9 (5) :e00879.